← All trials
NCT06835504
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2025
- Primary completion
- Aug 31, 2028
- Completion date
- Feb 28, 2029
- First posted
- Feb 19, 2025
- Last posted
- Feb 19, 2025
- Enrollment
- 1010
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Columbia UniversityLead sponsor
- Columbia UniversitySponsor investigator
- Medical College of WisconsinOfficial
- Columbia UniversityOfficial
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.